drugset
drugset / Trial / NCT02715570

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945

NCT02715570 ↗

Phase 1 Completed 29 enrolled Pulmocide Ltd
RandomizedCrossoverSingle-blindTreatment

Summary

PC945 is a new medicine being developed for treatment of fungal lung diseases. The main purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of PC945

Timeline

Start
2017-10-23
Primary completion
2018-04-27
Completion
2018-04-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Opelconazole Small molecule — Inhaled

Indications

aspergillosis